KRAS has proved impossible to target despite being a frequent variation (~20% of non-small-cell lung cancer [NSCLC]), due to the molecular structure which naturally inhibits medication binding. Smokers and mucinous histology are 2 unique clinical characteristics linked to KRAS mutations in NSCLC. About ~40% of KRAS-altered NSCLCs have G12C mutations, however, NSCLC is a disease that varies regionally, thus the symptoms can be different in this region. The case study of KRAS-mutated NSCLC included clinical, imaging, pathologic, therapy, and outcome data from a single center.

KRAS-mutated NSCLC was the subject of the 1-center retrospective investigation. The hospital’s medical record archives were searched for and used to gather the clinicopathological characteristics and results.

The 163 individuals who underwent testing for KRAS changes included 50 (30.6%) patients with advanced-stage NSCLC with KRAS mutations. The average age was 61. Three primary forms of KRAS mutations, namely G12C in 17 (34%), G12V in 9 (18%), and G12D in 6 (12%) individuals, were identified using molecular identification. Co-mutations were frequent in the non-G12C subgroup when compared to the G12C instances (P< 0.05). Chemotherapy was the initial line of treatment for all 36 patients who were seen at the facility, with a median progression-free survival (PFS) of 5.4 months. Compared to the non-G12C category, the PFS of G12C was greater (6.4 vs 3.8 months).

It was the greatest single-center experience with KRAS-mutated NSCLC with distinctive clinical characteristics from the Indian subcontinent. It drew attention to the unmet need for G12C inhibitors in the nation, where prevalence was comparable to that of the West.